CORRESPONDENCE

Pitfalls in the determination of mutant alleles of the thiopurine methyltransferase gene
TO THE EDITOR
Thiopurine methyltransferase (TPMT) is a methylating enzyme which is involved in the metabolism of thiopurines. The enzyme is known to exhibit an autosomal codominant polymorphism with 89-94% of all individuals studied having a high activity, 6-11% an intermediate activity and 0.3% having a very low or non-detectable activity. The gene encoding TPMT is localized on chromosome 6. Eight variant alleles of the gene are reported to be associated with decreased TPMT enzyme activity, and TPMT*3 mutations are the most prevalent. 1, 2 Heterozygotes and homozygotes for these alleles are at moderate and high risk, respectively, for thiopurine drug toxicity. In Caucasians and South West Asians, TPMT*3A (transitions G460A and A719G) is the most prevalent mutant allele whereas in a Chinese, a Korean and an African population, as well as an African-American population the TPMT*3C (A719G) mutation is more common. The TPMT*3A allele is believed to have arisen as a result of a TPMT*3B (G460A) mutation on an ancestral TPMT*3C variant allele. 1 From reviewing the literature on TPMT populations studies and from our own genotyping, we note that 19 cases of TPMT*3B have been reported from a total of 12 208 alleles, a frequency of 0.16%. [3] [4] [5] [6] [7] The mutations TPMT*3A and TPMT*3C accounted for 4.00% (488 alleles) and 1.38% (168 alleles), respectively, of the total amount of alleles published.
The A719G (TPMT*3C) mutation creates an Accl recognition sequence and the G460A (TPMT*3B) mutation destroys a Mwol site. 2 Using the method described by Yates et al 8 we have screened 116 children who were or had been suffering from acute lymphoblastic leukemia (ALL); eight of these children were screened after presentation of toxicologic features during thiopurine treatment. We also genotyped 43 control children not suffering from any hematological disorders. Twenty children were found to carry one or two mutant alleles. Unexpectedly, we found TPMT*3B heterozygotes and one patient homozygous for TPMT*3B (Table 1 ). In view of the low occurrence of the TPMT*3B allele, we expected that these alleles were 'misdiagnosed' and resulted from incomplete restriction endonuclease digestion.
These patients were re-examined using a stringent restriction endonuclease digestion protocol. PCR products were desalted by microdialysis on Millipore VS type filters (Pall Corporation, Ann Arbor, MI, USA) prior to an extended overnight digestion. In order to detect inhibitors of digestion, a dialysed PCR product was spiked with DNA known to contain appropriate restriction endonuclease sites. Using this protocol, we confirmed that incomplete Accl digestion of the A719G mutation resulted in TPMT*3A alleles being mistaken for TPMT*3B alleles. Theoretically, having a TPMT*3A or a TPMT*3B allele could have implications for the residual TPMT-activity and therefore for the amount of thiopurine tolerated. Expressing TPMT*3A and TPMT*3B in yeast, Tai et al 9 showed a 50-fold higher protein level for TPMT*3B, as compared to TPMT*3A. The Spearman rank correlation between erythrocyte TPMT-activity and amount of TPMT protein in the erythrocytes was 0.99, which was highly significant. However, it is premature to conclude that this indeed is of clinical significance.
Problems with partial digestion were however not limited to Accl: in one wild-type patient partial digestion by Mwol of the wild-type G460 resulted in the misdiagnosis of a TPMT*3B/*1 heterozygote. To further prevent misdiagnosis of the TPMT*3B allele positive and negative controls are needed.
Since the occurrence of the TPMT*3B allele is so low, as it seems to occur with a frequency of less than 1:500, the allele cannot be considered to be a significant risk allele for thiopurine drug toxicity. By extension, since the TPMT*3B allele occurs with an extremely low frequency, TPMT*3B/TPMT*3C compound heterozygotes (which cannot be discriminated from TPMT*3A heterozygotes by PCR) are unlikely to pose a significant diagnostic dilemma. However, one case of a TPMT*3B/TPMT*3C compound heterozygote has been reported recently and this finding seems to be significant, because the mutations were characterized at the cDNA level using a hybridization probe assay. 7 However, the TPMT*3B and TPMT*3C mutations in this patient were shown to occur alone on assayed cDNA clones and in our opinion this does not provide conclusive evidence of the existence of the TPMT*3B genotype. The anchor probes used in the assay were designed for genomic DNA, spanned intron-exon boundaries and were thus not fully complementary to the TMPT cDNA target. In addition, the results were not confirmed by DNA sequencing.
In our study we found patients with a homozygous TPMT*3A mutant genotype had TPMT-activities ranging from nondetectable to 2.8 pmol/10 7 RBC/h. We also found two apparent TPMT*3B/TPMT* 3C compound heterozygotes, accompanied with very low TPMTactivities of 2.2 and 3.2 pmol/10 7 RBC/h. To investigate whether one or two alleles were affected, PCR products were cloned using the pGEM-T Kit (Promega, Madison, WI, USA). These PCR products of 630 bp were obtained by amplifying cDNA with a forward primer located in exon 5 and a reverse primer being located in exon 10, thus containing both sites of interest. One wild-type was included as a control. Plasmid DNA was isolated and screened for the presence of the inserted fragment. The genotype of the plasmid DNA samples with the correct inserted fragment was examined by double digestion with Accl and Mwol. Both mutant cases appeared to be TPMT*3A heterozygotes.
With increasing awareness of the role of TPMT in thiopurine drug metabolism, we anticipate a considerable increase in requests for TPMT genotype. We hope that our experience will serve as a salutary warning to TPMT genotype service providers. 
London, UK
Predicting the presence or absence of ringed sideroblasts in patients suspected of having a myelodysplastic syndrome and increased iron stores: a simple observation
TO THE EDITOR
Refractory anemia with ringed sideroblasts (RARS) is one of the various myelodysplastic syndromes. It is characterized by 15% or more ringed sideroblasts in the bone marrow, 1 increased bone marrow iron stores 2 and less than 5% blasts in the bone marrow or less than 1% blasts in the peripheral blood. 3 Ringed sideroblasts are erythroid precursors that have perinuclear aggregates of iron-laden mitochondria. 4 Iron stores and ringed sideroblasts are demonstrated by staining the bone marrow smears with an acid potassium ferrocyanide solution (Prussian blue). 5 Increased hemosiderin deposits are commonly seen in chronically transfused patients for various reasons including chemotherapy induced anemia. 6 Myelodysplastic syndromes quite frequently have increased bone marrow iron stores. 7 Increased iron deposits in patients with RARS have been described as finely granular or rarely coarsely granular. 8 In hemosiderosis due to chronic transfusions the intracytoplasmic iron granules are large. 2 We have observed that specific patterns of iron distribution are associated with the presence or absence of ringed sideroblasts ascertained with low power (4×-10×) light microscopy.
Prussian blue-stained bone marrow aspirate smears were reviewed from 58 adult and pediatric patients reported to have increased iron stores from 1993 to 2000 at Geisinger Medical Center in the Department of Laboratory Medicine. Twenty-seven patients were identified as having RARS. Thirty-one patients were chosen as controls on the basis of having increased bone marrow stores and a diagnosis other than RARS. The first bone marrow examination in patients with the diagnosis of RARS was used since the majority of these patients had multiple bone marrow examinations after the diagnosis was made and the iron staining pattern can change over time. The control group included various diagnoses such as acute myelogenous leukemia, acute lymphoblastic leukemia, Hodgkin's and non-Hodgkin's lymphoma, end-stage renal disease, reactive marrow, chronic lymphocytic leukemia, metastatic small cell carcinoma, immune thrombocytopenic purpura, essential thrombocytemia, monoclonal gammopathy of unknown significance and a normal marrow. Many of these patients had been chronically transfused and received chemotherapy for their respective malignancies. In cases where more than one smear was discovered for a single patient, the chronologically first smear was used for inclusion in the study. Laboratory computer records were reviewed to identify which patients had been multiply transfused. Geisinger Medical Center's Institution Research Review Board approved the study.
The iron-stained slides were randomly arranged in trays and independently reviewed by two observers (RPD and MA) with no knowledge of the previous diagnoses. The investigators classified the morphologic pattern of each case on low power light microscopy into three categories: a diffuse pattern, a punctate pattern and a mixed pattern. Few inter-observer discrepancies were encountered. These mostly occurred with the mixed pattern and were reviewed simultaneously by both microscopists to reach a consensus. A diffuse pattern was defined as that in which the hemosiderin deposits are finely granular and diffusely distributed throughout the marrow particles appearing as a hazy bluish stain over the fat globules (Figure 1) . A punctate pattern was defined as that in which coarse granular iron deposits are heavily concentrated in and around macrophages in the particles. The focal distribution of iron within histiocytes gives it the punctate appearance and leaves the other marrow elements in the particle clearly visible (Figure 2) . A mixed pattern was defined as a hybrid between the diffuse and punctate patterns.
After classifying the patients by morphologic pattern, data analyses were conducted to determine if the presence or absence of ringed sideroblasts could be predicted by low power examination of the ironstained marrow aspirate slide. The chi-square test or the Fisher's exact test (in cases of small samples) was used to test for differences in prevalence of a punctate morphologic pattern. SAS 8.01 (Statistical Analysis Systems, Cary, NC, USA) was used for all data manipulations and analyses.
A total of 58 different patients' bone marrow aspirate iron stains with increased hemosiderin deposits were reviewed. Twenty-seven patients had the diagnosis of RARS. Thirty-one patients did not have the diagnosis of RARS and were thus identified as the control group (see Table 1 ).
Of the 27 patients with the diagnosis of RARS, none (0%) had a pure punctate pattern. All 27 (100%) of the patients with RARS had a diffuse pattern originally (26 with pure diffuse and one with a mixed diffuse and punctate pattern). In the 31 control patients, 13 (42%) had a pure punctate pattern, 15 (48%) had a diffuse pattern and three (10%) had a mixed pattern. Thus, patients with a diagnosis of RARS were more likely to have a diffuse pattern at the time they are first
